Biohaven strikes $100 million deal with Japan’s Ono Pharma for next-generation autoimmune disease drugs

Ono will secure exclusive rights to develop and commercialize Biohaven’s MoDE pan-IgG degrader portfolio in Japan, South Korea, Taiwan and the Association of Southeast Asian Nations (ASEAN) region
Read the full report on Indianpharmapost
Story file
- Section
- Health
- First reported by
- Indianpharmapost
- Published
- Sunday, 11 October 2026, 12:00 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Indianpharmapost with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.



